MX2024001645A - Metodo para el tratamiento de las enfermedades virales veterinarias. - Google Patents
Metodo para el tratamiento de las enfermedades virales veterinarias.Info
- Publication number
- MX2024001645A MX2024001645A MX2024001645A MX2024001645A MX2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- feline
- viral diseases
- viral
- treating
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 241000282324 Felis Species 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282465 Canis Species 0.000 abstract 1
- 208000000655 Distemper Diseases 0.000 abstract 1
- 241000283073 Equus caballus Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 206010051497 Rhinotracheitis Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 208000014058 canine distemper Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000005098 feline infectious peritonitis Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21190172 | 2021-08-06 | ||
| EP22185716 | 2022-07-19 | ||
| PCT/EP2022/072074 WO2023012329A1 (en) | 2021-08-06 | 2022-08-05 | Method of treating veterinary viral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001645A true MX2024001645A (es) | 2024-02-27 |
Family
ID=83151800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001645A MX2024001645A (es) | 2021-08-06 | 2022-08-05 | Metodo para el tratamiento de las enfermedades virales veterinarias. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240342204A1 (OSRAM) |
| EP (1) | EP4380578A1 (OSRAM) |
| JP (1) | JP2024528237A (OSRAM) |
| AU (1) | AU2022323465A1 (OSRAM) |
| BR (1) | BR112024002195A2 (OSRAM) |
| CA (1) | CA3226836A1 (OSRAM) |
| MX (1) | MX2024001645A (OSRAM) |
| WO (1) | WO2023012329A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002233A (es) | 2020-08-24 | 2023-03-15 | Gilead Sciences Inc | Compuestos fosfolipidos y usos de estos. |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0411900B8 (pt) | 2003-06-26 | 2021-05-25 | Biotron Ltd | compostos e composições farmacêuticas compreendendo os mesmos |
| WO2012152317A1 (en) | 2011-05-10 | 2012-11-15 | Okapi Sciences Nv | Compounds for use in the treatment of feline retroviral infections |
| GB201203180D0 (en) | 2012-02-24 | 2012-04-11 | Okapi Sciences Nv | Compounds for treating parvovirus infection |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| IL277160B2 (en) | 2018-03-07 | 2024-10-01 | Univ Emory | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
-
2022
- 2022-08-05 WO PCT/EP2022/072074 patent/WO2023012329A1/en not_active Ceased
- 2022-08-05 EP EP22762011.9A patent/EP4380578A1/en active Pending
- 2022-08-05 MX MX2024001645A patent/MX2024001645A/es unknown
- 2022-08-05 US US18/294,592 patent/US20240342204A1/en active Pending
- 2022-08-05 AU AU2022323465A patent/AU2022323465A1/en active Pending
- 2022-08-05 BR BR112024002195A patent/BR112024002195A2/pt unknown
- 2022-08-05 JP JP2024506795A patent/JP2024528237A/ja active Pending
- 2022-08-05 CA CA3226836A patent/CA3226836A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023012329A1 (en) | 2023-02-09 |
| EP4380578A1 (en) | 2024-06-12 |
| AU2022323465A1 (en) | 2024-02-01 |
| US20240342204A1 (en) | 2024-10-17 |
| JP2024528237A (ja) | 2024-07-26 |
| BR112024002195A2 (pt) | 2024-04-30 |
| CA3226836A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519553A5 (OSRAM) | ||
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| CA2682254A1 (en) | 1,3-oxathiolane nucleoside analogues | |
| RU2411039C2 (ru) | Иммунокорригирующее средство для лечения заболеваний вирусной этиологии | |
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| JP2023520323A5 (OSRAM) | ||
| CA2452075A1 (en) | Sustained release delivery system | |
| BR112024002195A2 (pt) | USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMAL | |
| ES2142873T3 (es) | Metodo para tratar infecciones virales. | |
| ES2033548T3 (es) | Procedimiento para la preparacion de derivados de purina. | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| Sabroe et al. | Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. | |
| CN112439058A (zh) | 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法 | |
| WO2021175250A1 (en) | Compounds and methods for treating diseases and/or conditions caused by coronavirus | |
| Kohara et al. | Effects of interferon-τ on cattle persistently infected with bovine viral diarrhea virus | |
| WO2008036747A2 (en) | Composition and method for immunomodulation | |
| JP2023533041A5 (OSRAM) | ||
| JP2024528237A5 (OSRAM) | ||
| WO2022079205A1 (en) | Use of ifn-alpha polypeptides for the treatment of coronavirus infections | |
| US20230203120A1 (en) | Hybrid interferons for treating viral infections | |
| GB2604052A (en) | Swine maternal neonatal pheromone | |
| Werenne et al. | Antiviral effect of bacterially produced human interferon (Hu-IFNα2) against experimental vaccinia infection in calves | |
| FR2694693B1 (fr) | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. | |
| TW528599B (en) | Stimulation of host defense mechanisms against viral challenges | |
| Loveridge et al. | CrOCOClile Immobilization and Anaesthesia |